Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 215

1.

MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan.

Tullo S, Patel R, Devenyi GA, Salaciak A, Bedford SA, Farzin S, Wlodarski N, Tardif CL; PREVENT-AD Research Group, Breitner JCS, Chakravarty MM.

Hum Brain Mapp. 2019 Aug 26. doi: 10.1002/hbm.24771. [Epub ahead of print]

PMID:
31452289
2.

No apparent effect of naproxen on CSF markers of innate immune activation.

Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group.

Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun.

3.

The Telephone Interview for Cognitive Status.

Breitner JCS.

Cogn Behav Neurol. 2018 Sep;31(3):159. doi: 10.1097/WNN.0000000000000167. No abstract available.

PMID:
30239468
4.

Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.

Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14.

PMID:
29735156
5.

Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.

Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative* and the PREVENT-AD Research Group.

Brain. 2018 Jun 1;141(6):1871-1883. doi: 10.1093/brain/awy093.

6.

Alterations in cholesterol metabolism-related genes in sporadic Alzheimer's disease.

Picard C, Julien C, Frappier J, Miron J, Théroux L, Dea D; United Kingdom Brain Expression Consortium and for the Alzheimer's Disease Neuroimaging Initiative, Breitner JCS, Poirier J.

Neurobiol Aging. 2018 Jun;66:180.e1-180.e9. doi: 10.1016/j.neurobiolaging.2018.01.018. Epub 2018 Feb 9.

PMID:
29503034
7.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

8.

Author response: Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Breitner JCS.

Neurology. 2018 Feb 13;90(7):343. doi: 10.1212/WNL.0000000000004959. No abstract available.

PMID:
29440548
9.

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.

Tuwaig M, Savard M, Jutras B, Poirier J, Collins DL, Rosa-Neto P, Fontaine D, Breitner JCS; PREVENT-AD Research Group.

J Alzheimers Dis. 2017;60(4):1589-1600. doi: 10.3233/JAD-170545.

10.

Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group.

Neurology. 2017 Jul 25;89(4):327-335. doi: 10.1212/WNL.0000000000004159. Epub 2017 Jun 28.

11.

Comment: MCI trials-Categorical "square pegs" in dimensional "round holes"?

Breitner JCS.

Neurology. 2017 May 2;88(18):1757. doi: 10.1212/WNL.0000000000003893. Epub 2017 Apr 5. No abstract available.

PMID:
28381505
12.

Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model.

Cavanagh C, Tse YC, Nguyen HB, Krantic S, Breitner JC, Quirion R, Wong TP.

Neurobiol Aging. 2016 Nov;47:41-49. doi: 10.1016/j.neurobiolaging.2016.07.009. Epub 2016 Jul 25.

13.

How can we really improve screening methods for AD prevention trials?

Breitner JCS.

Alzheimers Dement (N Y). 2016 Feb 2;2(1):45-47. doi: 10.1016/j.trci.2015.12.004. eCollection 2016 Jan. Review. No abstract available.

14.

Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).

Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.

J Prev Alzheimers Dis. 2016;3(4):236-242. doi: 10.14283/jpad.2016.121.

PMID:
29199324
15.

'Alzheimer's Progression Score': Development of a Biomarker Summary Outcome for AD Prevention Trials.

Leoutsakos JM, Gross AL, Jones RN, Albert MS, Breitner JCS.

J Prev Alzheimers Dis. 2016;3(4):229-235. doi: 10.14283/jpad.2016.120.

16.

Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease.

Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group.

Sci Data. 2015 Oct 13;2:150043. doi: 10.1038/sdata.2015.43. eCollection 2015.

17.

Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.

Chuang YF, An Y, Bilgel M, Wong DF, Troncoso JC, O'Brien RJ, Breitner JC, Ferruci L, Resnick SM, Thambisetty M.

Mol Psychiatry. 2016 Jul;21(7):910-5. doi: 10.1038/mp.2015.129. Epub 2015 Sep 1.

18.

Comment: Yet another "disconnect" between amyloid and Alzheimer disease?

Breitner JC.

Neurology. 2015 Aug 25;85(8):698. doi: 10.1212/WNL.0000000000001871. Epub 2015 Jul 24. No abstract available.

PMID:
26208958
19.

Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages.

Colby-Milley J, Cavanagh C, Jego S, Breitner JC, Quirion R, Adamantidis A.

PLoS One. 2015 Jun 15;10(6):e0130177. doi: 10.1371/journal.pone.0130177. eCollection 2015.

20.

Encouraging trends toward reduced risk of Alzheimer disease: What's good for the heart is good for the brain.

Breitner JCS, Galasko D.

Neurol Clin Pract. 2015 Jun;5(3):190-192. doi: 10.1212/CPJ.0000000000000110. No abstract available.

Supplemental Content

Loading ...
Support Center